Re: AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer

被引：3
|
作者：
Taneja, Samir S.
机构：
来源：
JOURNAL OF UROLOGY | 2015年 / 193卷 / 02期
关键词：
D O I：
10.1016/j.juro.2014.11.066
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：538 / 538
页数：1
相关论文
共 50 条
  • [1] Re: AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
    Anand, Aseem Undvall
    Bjartell, Anders
    EUROPEAN UROLOGY, 2015, 67 (02) : 349 - 350
  • [2] Re: AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
    Sun, Maxine
    Abdollah, Firas
    EUROPEAN UROLOGY, 2015, 68 (01) : 162 - 163
  • [3] AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
    Antonarakis, Emmanuel S.
    Lu, Changxue
    Wang, Hao
    Luber, Brandon
    Nakazawa, Mary
    Roeser, Jeffrey C.
    Chen, Yan
    Mohammad, Tabrez A.
    Chen, Yidong
    Fedor, Helen L.
    Lotan, Tamara L.
    Zheng, Qizhi
    De Marzo, Angelo M.
    Isaacs, John T.
    Isaacs, William B.
    Nadal, Rosa
    Paller, Channing J.
    Denmeade, Samuel R.
    Carducci, Michael A.
    Eisenberger, Mario A.
    Luo, Jun
    NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (11): : 1028 - 1038
  • [4] AR-V7 associated with resistance to enzalutamide and abiraterone
    Reactions Weekly, 2014, 1520 (1) : 6 - 6
  • [5] The association of AR-V7 with resistance to Abiraterone in metastatic castration-resistant prostate cancer
    Wang, Shuo
    Cao, Yudong
    Tang, Xingxing
    Yang, Xiao
    Ma, Jinchao
    Yu, Ziyi
    Yang, Yong
    Du, Peng
    JOURNAL OF MENS HEALTH, 2022, 18 (03)
  • [6] KIF15-Mediated Stabilization of AR and AR-V7 Contributes to Enzalutamide Resistance in Prostate Cancer
    Gao, Lin
    Zhang, Wenbo
    Zhang, Jing
    Liu, Junmei
    Sun, Feifei
    Liu, Hui
    Hu, Jing
    Wang, Xin
    Wang, Xueli
    Su, Peng
    Chen, Shouzhen
    Qu, Sifeng
    Shi, Benkang
    Xiong, Xueting
    Chen, Weiwen
    Dong, Xuesen
    Han, Bo
    CANCER RESEARCH, 2021, 81 (04) : 1026 - 1039
  • [7] Combination of CAPE with enzalutamide or abiraterone suppresses drug-resistant prostate cancer via AR-V7 degradation
    Kuo, Yingyu
    Huo, Chieh
    Chuu, Chihpin
    CANCER SCIENCE, 2024, 115 : 316 - 316
  • [8] The Crucial Role of AR-V7 in Enzalutamide-Resistance of Castration-Resistant Prostate Cancer
    Zheng, Zeyuan
    Li, Jinxin
    Liu, Yankuo
    Shi, Zhiyuan
    Xuan, Zuodong
    Yang, Kunao
    Xu, Chunlan
    Bai, Yang
    Fu, Meiling
    Xiao, Qiaohong
    Sun, Huimin
    Shao, Chen
    CANCERS, 2022, 14 (19)
  • [9] Androgen receptor splice variant, AR-V7, and resistance to enzalutamide and abiraterone in men with metastatic castration-resistant prostate cancer (mCRPC)
    Antonarakis, Emmanuel S.
    Lu, Changxue
    Wang, Hao
    Luber, Brandon
    Nakazawa, Mary
    Chen, Yan
    Roeser, Jeffrey C.
    Fedor, Helen L.
    Lotan, Tamara L.
    Zheng, Qizhi
    De Marzo, Angelo M.
    Isaacs, John T.
    Isaacs, William B.
    Nadal, Rosa
    Paller, Channing Judith
    Denmeade, Samuel R.
    Carducci, Michael Anthony
    Eisenberger, Mario A.
    Luo, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [10] Androgen Receptor Variant AR-V9 Is Coexpressed with AR-V7 in Prostate Cancer Metastases and Predicts Abiraterone Resistance
    Kohli, Manish
    Ho, Yeung
    Hillman, David W.
    Van Etten, Jamie L.
    Henzler, Christine
    Yang, Rendong
    Sperger, Jamie M.
    Li, Yingming
    Tseng, Elizabeth
    Hon, Ting
    Clark, Tyson
    Tan, Winston
    Carlson, Rachel E.
    Wang, Liguo
    Sicotte, Hugues
    Ho Thai
    Jimenez, Rafael
    Huang, Haojie
    Vedell, Peter T.
    Eckloff, Bruce W.
    Quevedo, Jorge F.
    Pitot, Henry C.
    Costello, Brian A.
    Jen, Jin
    Wieben, Eric D.
    Silverstein, Kevin A. T.
    Lang, Joshua M.
    Wang, Liewei
    Dehm, Scott M.
    CLINICAL CANCER RESEARCH, 2017, 23 (16) : 4704 - 4715
12345